Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by O'connor, N.
Right arrow Articles by Jones, A.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'connor, N.
Right arrow Articles by Jones, A.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2003; 96: 787-791
© 2003 Association of Physicians

Review

Hepatocellular damage from non-steroidal anti-inflammatory drugs

N. O'connor1, P.I. Dargan2 and A.L. Jones2

From the 1Emergency Department and 2National Poisons Information Service (London), Guy’s and St Thomas’ NHS Trust, London, UK

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for the management of rheumatological disorders, and as analgesics and antipyretics. Hepatotoxicity is an uncommon, but potentially lethal complication, which usually occurs within 12 weeks of starting therapy. It can occur with all NSAIDs, but appears to be more common with diclofenac and particularly sulindac. Female patients aged >50 years, with autoimmune disease, and those on other potentially hepatotoxic drugs, appear to be particularly susceptible. Liver function test abnormalities generally settle within 4–6 weeks of stopping the causative drug. However, some patients may develop acute liver failure and successful orthotopic liver transplantation may be undertaken in such patients. Recent in vitro animal studies have shown that the mechanism of diclofenac toxicity relates both to impairment of ATP synthesis by mitochondria, and to production of active metabolites, particularly n,5-dihydroxydiclofenac, which causes direct cytotoxicity. Mitochondrial permeability transition (MPT) has also been shown to be important in diclofenac-induced liver injury, resulting in generation of reactive oxygen species, mitochondrial swelling and oxidation of NADP and protein thiols. Physicians and hepatologists must be vigilant to the hepatotoxic potential of any NSAID, as increased awareness, surveillance and reporting of these events will lead to a better understanding of the risk factors and the pathophysiology of NSAID-related hepatotoxicity.

Address correspondence to Dr A.L. Jones, National Poisons Information Service (London), Guy’s and St Thomas’ NHS Trust, Avonley Road, London SE14 5ER. e-mail: alison.jones{at}gstt.sthames.nhs.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
W. Zou, K. M. Beggs, E. M. Sparkenbaugh, A. D. Jones, H. S. Younis, R. A. Roth, and P. E. Ganey
Sulindac Metabolism and Synergy with Tumor Necrosis Factor-{alpha} in a Drug-Inflammation Interaction Model of Idiosyncratic Liver Injury
J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 114 - 121.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.